Stereotaxis Secures Approval for Next-Gen System and Reports Year-Over-Year Revenue Growth
During Q1 2026, Stereotaxis announced regulatory approvals for its next-generation catheter navigation system and reported year-over-year revenue growth driven by increased US hospital deployments. Executives detailed planned FDA submissions for expanded indications and confirmed European market launch in H2 2026.
1. Q1 2026 Earnings Call Highlights
In the Q1 2026 earnings call, Stereotaxis announced regulatory approvals for its next-generation catheter navigation system, highlighting growth in US hospital deployments that drove year-over-year revenue gains. Management detailed ongoing FDA submissions for expanded device indications and reaffirmed plans to launch commercial operations in Europe during the second half of 2026.
Related News
NVDA
Nvidia’s AI Chip Revenue Forecast Beats Estimates but Shares Drop 1.3%
NVDA•
LOW
Lowe's Q1 Profit Falls to $1.62 Billion as Revenues Surge 10.3% to $23.07 Billion
LOW•
ELF
e.l.f. Beauty Marks 29th Consecutive Sales Growth, Reinvests $58.5M Tariff Refunds
ELF•
NVDA
Nvidia posts $81.6bn Q1 revenue, raises dividend 25-fold and authorizes $80bn buyback
NVDA•
ZKH
ZKH Group 1Q GMV Rises 12.9% to RMB2.45B; Non-GAAP EBITDA Positive
ZKH•
Sources
F